The global immunotherapy drugs market size was estimated at USD 257.6 billion in 2024 and is projected to reach USD 486.36 billion by 2030, growing at a CAGR of 11.2% from 2025 to 2030. This robust market growth is primarily fueled by the increasing prevalence of chronic diseases worldwide, which continues to create strong demand for advanced treatment options.

According to data from the International Diabetes Federation (IDF), around 537 million adults aged between 20 and 79 were living with diabetes in 2021. This number is expected to surge to 783 million by 2045, highlighting the growing global health burden that is driving the need for innovative therapies. In response, key players in the immunotherapy drug industry are actively investing in research and development by introducing new products and forming strategic partnerships aimed at accelerating scientific advancements and enhancing treatment efficacy.

Several critical factors are propelling the market forward, including the rising incidence of chronic illnesses such as cancer, as well as an increasing patient and physician preference for therapies that empower the immune system to combat diseases more effectively. Immunotherapy stands out as a promising alternative to conventional treatments by specifically targeting disease-causing cells, often resulting in fewer side effects and improved patient outcomes. Within this market, major drug categories include monoclonal antibodies and immune checkpoint inhibitors, both of which have gained widespread acceptance in clinical settings as effective treatment modalities for a variety of medical conditions.

Key Market Trends & Insights:

• In 2024, the North America immunotherapy market held a commanding position in the global landscape, accounting for a substantial 41.87% share of the total market revenue. This dominance underscores the region's advanced healthcare infrastructure, significant investments in medical research, and widespread adoption of innovative therapies. Within North America, the United States stands out as a key driver of market growth and is expected to experience a notable compound annual growth rate (CAGR) throughout the forecast period, reflecting increasing demand for immunotherapy drugs and ongoing advancements in treatment options.

• When examining the market by drug type, the monoclonal antibodies segment emerged as the leader in 2024, capturing the largest share of 55.26% of the market revenue. This prominence is due to the widespread use of monoclonal antibodies in targeting specific disease markers, making them a preferred choice for treating various conditions.

• By medical indication, the cancer segment dominated the immunotherapy drugs market, contributing a significant 87.88% to the overall revenue in 2024. This highlights the critical role immunotherapy plays in oncology, where it is increasingly recognized as an effective treatment option for various types of cancer, helping to improve patient outcomes and survival rates.

Order a free sample PDF of the Immunotherapy Drugs Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 257.6 Billion

• 2030 Projected Market Size: USD 486.36 Billion

• CAGR (2025-2030): 11.2%

• North America: Largest market in 2024

Key Companies & Market Share Insights:

The immunotherapy drugs market is currently undergoing a significant transformation, largely propelled by the rising incidence of cancer and autoimmune diseases, alongside notable advancements in research and development within the pharmaceutical sector. This dynamic environment has attracted several key industry players, including Amgen Inc., Novartis AG, AbbVie, and Johnson & Johnson Services, Inc. Each of these companies holds a distinctive position within the market based on their specialized focus areas. For instance, Amgen Inc. is widely recognized for its innovative oncology therapies, while Novartis AG concentrates on developing highly targeted treatment options. AbbVie has carved out a niche in immunology, and Johnson & Johnson offers a broad spectrum of immunotherapy products spanning various therapeutic categories.

To maintain and strengthen their market presence, these companies are employing diverse growth strategies. These include mergers and acquisitions to broaden their capabilities, expanding their product portfolios to address a wider array of medical conditions, and increasing their investment in research and development (R&D) to pioneer new therapies designed to enhance the body's immune response. As the demand for more effective cancer treatments continues to grow, the immunotherapy drugs industry is expected to witness substantial expansion in the coming years.

Focusing on specific companies, Amgen Inc. is a prominent player within this market, dedicated to developing innovative therapies targeting both cancer and autoimmune disorders. The company is well known for its products like BLINCYTO, which is used to treat certain types of leukemia, and KYPROLIS, indicated for multiple myeloma. Amgen's commitment to improving cancer care is underscored by its robust pipeline of new therapies aimed at addressing unmet medical needs.

Similarly, Johnson & Johnson Services, Inc. holds a significant position in the immunotherapy drugs sector, offering a diverse range of therapies targeting various cancers and autoimmune diseases. The company has successfully developed several approved immunotherapy drugs that are widely recognized for their effectiveness and safety profiles. Johnson & Johnson emphasizes continuous innovation and high-quality standards to ensure their products effectively meet patient needs. Additionally, the company actively pursues strategic partnerships to bolster its research capabilities and broaden market access, enabling it to remain competitive in the rapidly evolving landscape of immunotherapy.

Key Players

• Amgen Inc.

• Novartis AG

• AbbVie Inc.

• Pfizer Inc.

• F. Hoffmann-La Roche Ltd

• Johnson & Johnson Services, Inc.

• AstraZeneca

• GSK plc.

• Sanofi

• Bayer AG

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global immunotherapy drugs market is experiencing significant growth, driven by the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases. Advancements in research and development, along with supportive government policies, are contributing to the expansion of the market. North America holds a dominant position in the global market, benefiting from advanced healthcare infrastructure and substantial investments in medical research. The market is characterized by a diverse range of drug types, including monoclonal antibodies, immunomodulators, and vaccines, catering to various medical indications. As the demand for effective treatments continues to rise, the immunotherapy drugs industry is poised for sustained growth in the coming years.